March 2, 2018 Source: MobiHealthNews 183
Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
“At AlertWatch, we believe that integrating multiple streams of data into a live, readily identifiable icon display can improve the safety of acute care medicine just as it has done in modern aviation,” Dr. Kevin Tremper, founder and president of AlertWatch, said in a statement. “Collaborating with Qualcomm Life to offer our service in tandem with the Capsule product line will increase the reach of AlertWatch and help enhance patient monitoring throughout the hospital.”
The watch was first developed at the University of Michigan Health System and uses data from Qualcomm Life’s Capsule platform combined with EHR feeds to give real-time information to anesthesiologists during a surgery.
Qualcomm Life has also announced a deal with PeriGen, a company that makes perinatal software products that give clinicians more patient data based on algorithms and analysis. This deal will let Qualcomm Life license and sell PeriWatch Vigilance, which is a new platform that identify obstetrics patients whose conditions are deteriorating, and aims to create timely interventions.
“As we grow our intelligent care product platform, we look to collaborate with companies that monitor patients and provide actionable insights for physicians and care teams,” Dr. James Mault, senior vice president and chief medical officer of Qualcomm Life, said in a statement. “Our collaboration with PeriGen marks the first of Qualcomm Life’s obstetric applications and we are thrilled to be able to work with PeriGen in an effort to garner new insights that enable providers to deliver better care to their patients.”
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.